BR112020009173A2 - uso de profármacos de rizulol para tratar ataxias - Google Patents

uso de profármacos de rizulol para tratar ataxias Download PDF

Info

Publication number
BR112020009173A2
BR112020009173A2 BR112020009173-1A BR112020009173A BR112020009173A2 BR 112020009173 A2 BR112020009173 A2 BR 112020009173A2 BR 112020009173 A BR112020009173 A BR 112020009173A BR 112020009173 A2 BR112020009173 A2 BR 112020009173A2
Authority
BR
Brazil
Prior art keywords
ataxia
rizulol
prodrug
fact
patient
Prior art date
Application number
BR112020009173-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Vladimir Coric
Robert Berman
Melissa Beiner
Gilbert L'italien
Original Assignee
Biohaven Pharmaceutical Holding Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020009173(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biohaven Pharmaceutical Holding Company Ltd. filed Critical Biohaven Pharmaceutical Holding Company Ltd.
Publication of BR112020009173A2 publication Critical patent/BR112020009173A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020009173-1A 2017-11-12 2018-11-11 uso de profármacos de rizulol para tratar ataxias BR112020009173A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US62/584,856 2017-11-12
US201862717948P 2018-08-13 2018-08-13
US62/717,948 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
BR112020009173A2 true BR112020009173A2 (pt) 2020-11-03

Family

ID=66438598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020009173-1A BR112020009173A2 (pt) 2017-11-12 2018-11-11 uso de profármacos de rizulol para tratar ataxias

Country Status (26)

Country Link
US (3) US20210023061A1 (https=)
EP (4) EP4483956B1 (https=)
JP (2) JP7352542B2 (https=)
KR (2) KR20200103658A (https=)
CN (1) CN112292127A (https=)
AU (1) AU2018364749C1 (https=)
BR (1) BR112020009173A2 (https=)
CA (1) CA3082096A1 (https=)
DK (2) DK3706739T3 (https=)
ES (1) ES2996892T3 (https=)
FI (2) FI3706739T3 (https=)
HR (1) HRP20241675T1 (https=)
HU (1) HUE070302T2 (https=)
IL (1) IL274532B2 (https=)
LT (2) LT3706739T (https=)
MD (1) MD3706739T2 (https=)
MX (2) MX2020004678A (https=)
PH (1) PH12020550583A1 (https=)
PL (1) PL3706739T3 (https=)
PT (2) PT3706739T (https=)
RS (1) RS66277B1 (https=)
SG (1) SG11202004332XA (https=)
SI (1) SI3706739T1 (https=)
SM (1) SMT202500022T1 (https=)
WO (1) WO2019094851A1 (https=)
ZA (1) ZA202002626B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
PT1001748E (pt) 1997-07-25 2006-08-31 Alpex Pharma Sa Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Also Published As

Publication number Publication date
JP7352542B2 (ja) 2023-09-28
HUE070302T2 (hu) 2025-05-28
US20230355592A1 (en) 2023-11-09
KR20200103658A (ko) 2020-09-02
EP4699619A3 (en) 2026-05-06
RS66277B1 (sr) 2025-01-31
US20210023061A1 (en) 2021-01-28
PH12020550583A1 (en) 2021-05-31
CA3082096A1 (en) 2019-05-16
ZA202002626B (en) 2025-02-26
LT4483956T (lt) 2026-04-27
JP2021502392A (ja) 2021-01-28
PT3706739T (pt) 2024-12-04
CN112292127A (zh) 2021-01-29
EP4483956A2 (en) 2025-01-01
MD3706739T2 (ro) 2025-02-28
SI3706739T1 (sl) 2025-03-31
US20230390252A1 (en) 2023-12-07
AU2018364749A1 (en) 2020-07-02
WO2019094851A1 (en) 2019-05-16
DK4483956T3 (da) 2026-03-23
FI4483956T3 (fi) 2026-03-16
US12102618B2 (en) 2024-10-01
IL274532A (en) 2020-06-30
DK3706739T3 (da) 2024-12-02
EP4483956A3 (en) 2025-03-19
EP4696324A3 (en) 2026-05-06
PT4483956T (pt) 2026-03-16
PL3706739T3 (pl) 2025-03-10
SG11202004332XA (en) 2020-06-29
JP2023175823A (ja) 2023-12-12
EP4696324A2 (en) 2026-02-18
EP3706739A4 (en) 2021-08-04
EP4483956B1 (en) 2025-12-31
FI3706739T3 (fi) 2024-12-27
MX2023012640A (es) 2023-11-08
EP4699619A2 (en) 2026-02-25
HRP20241675T1 (hr) 2025-02-14
EP3706739B1 (en) 2024-10-16
LT3706739T (lt) 2024-12-27
KR20250034521A (ko) 2025-03-11
NZ765220A (en) 2023-11-24
IL274532B1 (en) 2024-01-01
ES2996892T3 (en) 2025-02-13
AU2018364749C1 (en) 2024-02-15
SMT202500022T1 (it) 2025-03-12
AU2018364749B2 (en) 2023-11-09
EP3706739A1 (en) 2020-09-16
MX2020004678A (es) 2020-08-13
IL274532B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
US12102618B2 (en) Use of riluzole prodrugs to treat ataxias
Ghika et al. Idazoxan treatment in progressive supranuclear palsy
CA3255652A1 (en) 5-meo-dtm for the treatment of bipolar disorder
CA3255340A1 (en) 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF BIPOLAR DISORDER
CN109069463A (zh) 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
CN109414507A (zh) 用于预防和治疗神经退行性疾病的高度选择性腺苷a3受体亚型激动剂
Grosso et al. Neuroprotection beyond intraocular pressure: Game changer or quiet addiction
EP4048249B1 (en) Methods of treating the symptoms of autism spectrum disorder
HK40118245A (en) Use of riluzole prodrugs to treat ataxias
Rutherford et al. Intravenous administration of nicotinamide adenine dinucleotide alleviates tremors associated with Parkinson’s disease: a case report
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
TW200916091A (en) Neramexane for the treatment of nystagmus
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
Heir et al. Orofacial dystonias and dyskinesias
Possin et al. Parkinsonian dementias
HK40080588B (en) Methods of treating the symptoms of autism spectrum disorder
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder
BR112020007657B1 (pt) Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls)
BR112020007657A2 (pt) leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento da síndrome das pernas inquietas (rls)
Tan P2. 107 A new syndrome with quadrupedal gait and primitive cognition

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]